Please assess the completion status of the following clinical trial:

Trial Title: A Phase 2/3 Study to Evaluate the Efficacy and Safety of CT-P59 in Patients With Mild to Moderate SARS-CoV-2 Infection

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2/PHASE3
- Number of Arms: 5.0

Eligibility Criteria:
Inclusion Criteria:~Patient had to meet all of the following criteria to be randomized in this study.~1. Patient was an adult male or female patient, aged 18 or above.~2. Patient was diagnosed with SARS-CoV-2 infection at Screening by using the sponsor-supplied rapid SARS-CoV-2 diagnostic test or RT-PCR (reverse transcription-polymerase chain reaction).~3. Patient with conditions meeting all of the following criteria:~   1. Oxygen saturation \> 94% on room air.~  2. Not requiring supplemental oxygen.~4. Patient who had an onset of symptom no more than 7 days prior to the study drug administration.~5. Patient had 1 or more of the SARS-CoV-2 infection-associated symptoms within but no more than 7 days prior to the study drug administration.~Exclusion Criteria:~Patients meeting any of the following criteria were excluded from the study.~1. Patient had current severe condition meeting one of the following:~   1. Previous or current hospitalization or requirement of hospitalization for treatment of serious SARS-CoV-2 related conditions.~  2. Respiratory distress with respiratory rate ≥30 breaths/min.~  3. Required supplemental oxygen~  4. Experienced shock~  5. Complicated with other organs failure, and intensive care unit monitoring treatment is needed by investigator's discretion.~2. Patient had received or had a plan to receive any of the following prohibited medications or treatments:~   1. Drugs with actual or possible antiviral drugs and/or possible anti-SARS-CoV-2 activity including but not limited to remdesivir, chloroquine, hydroxychloroquine, dexamethasone (or alternative corticosteroids to dexamethasone), interferon beta-1b, ribavirin, and other immunomodulatory agents and human immunodeficiency virus protease inhibitors (lopinavir-ritonavir, etc.) for therapeutic purpose of SARS-CoV-2 infection prior to study drug administration~  2. Any SARS-CoV-2 human IV immunoglobulin, convalescent plasma for the treatment of SARS-CoV-2 infection prior to study drug administration~  3. Any other investigational device or medical product including but not limited to any monoclonal antibody (tocilizumab, sarilumab, etc.), fusion proteins or biologics for the treatment of SARS-CoV-2 infection prior to the study drug administration~  4. Use of medications that are contraindicated with SoC~  5. SARS-CoV-2 vaccine prior to the study drug administration

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- CT-P59 40 mg/kg group (Part 1) (Type: EXPERIMENTAL): CT-P59 (regdanvimab), 40 mg/kg by IV infusion once
- CT-P59 80 mg/kg group (Part 1) (Type: EXPERIMENTAL): CT-P59 (regdanvimab), 80 mg/kg by IV infusion once
- Placebo group (Part 1) (Type: PLACEBO_COMPARATOR): Placebo, matching in volume of CT-P59 80 mg/kg by IV infusion once
- CT-P59 40 mg/kg group (Part 2) (Type: EXPERIMENTAL): CT-P59 (regdanvimab), 40 mg/kg by IV infusion once
- Placebo group (Part 2) (Type: PLACEBO_COMPARATOR): Placebo, matching in volume of CT-P59 40 mg/kg by IV infusion once

Based on this trial design, predict the completion outcome and termination type (if applicable).